U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula CH3O5P
Molecular Weight 126.0053
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FOSCARNET

SMILES

OC(=O)P(O)(O)=O

InChI

InChIKey=ZJAOAACCNHFJAH-UHFFFAOYSA-N
InChI=1S/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6)

HIDE SMILES / InChI

Molecular Formula CH3O5P
Molecular Weight 126.0053
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Foscarnet is an antiviral agent. Foscarnet shows activity against human herpesviruses and HIV. Foscarnet is used for treating eye problems caused by CMV in people with AIDS. It is also used to treat a type of HSV that cannot be treated by another medicine in people with a weak immune system. FOSCAVIR is the brand name for foscarnet sodium. FOSCAVIR is an organic analogue of inorganic pyrophosphate that inhibits replication of herpesviruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). FOSCAVIR exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virusspecific DNA polymerases at concentrations that do not affect cellular DNA polymerases. FOSCAVIR does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to FOSCAVIR.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
2.03 µM [IC50]
2.5 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FOSCAVIR

Cmax

ValueDoseCo-administeredAnalytePopulation
46.4 μM
90 mg/kg bw single, oral
FOSCARNET plasma
Homo sapiens
887.3 μM
90 mg/kg bw single, intravenous
FOSCARNET plasma
Homo sapiens
64.9 μM
180 mg/kg bw single, oral
FOSCARNET plasma
Homo sapiens
86.2 μM
90 mg/kg bw 1 times / day multiple, oral
FOSCARNET plasma
Homo sapiens
78.7 μM
90 mg/kg bw 2 times / day multiple, oral
FOSCARNET plasma
Homo sapiens
86.4 μM
180 mg/kg bw 1 times / day multiple, oral
FOSCARNET plasma
Homo sapiens
589 μM
60 mg/kg bw 3 times / day steady-state, intravenous
FOSCARNET plasma
Homo sapiens
623 μM
90 mg/kg bw 2 times / day steady-state, intravenous
FOSCARNET plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
300 μM × h
90 mg/kg bw single, oral
FOSCARNET plasma
Homo sapiens
3308 μM × h
90 mg/kg bw single, intravenous
FOSCARNET plasma
Homo sapiens
494 μM × h
180 mg/kg bw single, oral
FOSCARNET plasma
Homo sapiens
646 μM × h
90 mg/kg bw 1 times / day multiple, oral
FOSCARNET plasma
Homo sapiens
688 μM × h
90 mg/kg bw 2 times / day multiple, oral
FOSCARNET plasma
Homo sapiens
826 μM × h
180 mg/kg bw 1 times / day multiple, oral
FOSCARNET plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
6.7 h
90 mg/kg bw single, oral
FOSCARNET plasma
Homo sapiens
5.7 h
90 mg/kg bw single, intravenous
FOSCARNET plasma
Homo sapiens
5.4 h
180 mg/kg bw single, oral
FOSCARNET plasma
Homo sapiens
7.6 h
90 mg/kg bw 1 times / day multiple, oral
FOSCARNET plasma
Homo sapiens
5.7 h
90 mg/kg bw 2 times / day multiple, oral
FOSCARNET plasma
Homo sapiens
5.6 h
180 mg/kg bw 1 times / day multiple, oral
FOSCARNET plasma
Homo sapiens
4 h
60 mg/kg bw 3 times / day steady-state, intravenous
FOSCARNET plasma
Homo sapiens
3.3 h
90 mg/kg bw 2 times / day steady-state, intravenous
FOSCARNET plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
84.5%
60 mg/kg bw 3 times / day steady-state, intravenous
FOSCARNET plasma
Homo sapiens
84.5%
90 mg/kg bw 2 times / day steady-state, intravenous
FOSCARNET plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for CMV Retinitis Induction therapy: 90 mg/kg IV (90- to 120-minute infusion) every 12 hours or 60 mg/kg IV (minimum 1-hour infusion) every 8 hours over 2 to 3 weeks depending on clinical response Maintenance therapy: 90 to 120 mg/kg IV (2-hour infusion) once a day Usual Adult Dose for Herpes Simplex - Mucocutaneous/Immunocompromised Host Induction therapy: 40 mg/kg IV (minimum 1-hour infusion) every 8 or 12 hours Duration of therapy: 2 to 3 weeks or until healed Usual Adult Dose for CMV Gastroenteritis US CDC, NIH, and IDSA recommendations for the treatment of CMV esophagitis or colitis in HIV-infected patients: 60 mg/kg IV every 8 hours or 90 mg/kg IV every 12 hours
Route of Administration: Intravenous
In Vitro Use Guide
Foscarnet inhibits in vitro the replication of all herpes viruses, including human cytomegalovirus (HCMV) at concentrations of 100 to 300 umol/l and has a dose-related inhibitory effect on HIV-1 virus, influenza virus and hepatitis B virus.
Substance Class Chemical
Record UNII
364P9RVW4X
Record Status Validated (UNII)
Record Version